Association for Accessible Medicines

Call Directions Website

Association for Accessible Medicines Association for Accessible Medicines promotes policies, including greater competition, to ensure mor

The Association for Accessible Medicines promotes policies, including greater competition, to ensure more generic and biosimilar medicines are more accessible to more people who need them.

Biosimilar medicines are healthcare heroes—they promise additional savings for complex conditions, such as cancer and au...
10/15/2026

Biosimilar medicines are healthcare heroes—they promise additional savings for complex conditions, such as cancer and autoimmune diseases. Just as generics offer savings over brand drugs, biosimilars (the safe, effective alternative versions of biologic medicines) also promise to improve the quality of life for America’s patients. Unfortunately, biosimilar adoption continues to trail expectations because of poor reimbursement and misaligned incentives. Still, biosimilar medicines have generated $81.6B in savings in the past decade—a reflection of provider confidence and healthy competition. Learn more in AAM's 2026 U.S. Savings Report: https://accessiblemeds.org/resources/reports/2026-savings-report/

The wait is over—the full agenda for 2026 is now live: https://grxbiosims.org/agenda Join us Nov 2–4 as the generic a...
10/14/2026

The wait is over—the full agenda for 2026 is now live: https://grxbiosims.org/agenda

Join us Nov 2–4 as the generic and biosimilar medicines industry gathers for three days of scientific, regulatory, legal, and policy discussions featuring FDA leaders and industry experts.

As noted in the chart, examining the decreased costs and increased patient uptake after generic competition for Entresto...
10/13/2026

As noted in the chart, examining the decreased costs and increased patient uptake after generic competition for Entresto makes it clear that competition beats price controls. Entresto’s MFP was set at $295 starting in calendar year 2026 for all Medicare beneficiaries. According to an AAM analysis of IQVIA data, the average cost of a patient prescription for all U.S. sales was a little over $1,000 in Q2 of 2025. When more than a dozen generic companies began marketing the product in Q3 of 2025, over time, the number of Americans being able to afford the drug increased, while the overall price of both the reference product and the generic competition decreased. The bottom line: Healthy competition is the most proven approach to lowering drug costs. Learn more:https://accessiblemeds.org/resources/reports/2026-savings-report/

10/13/2026

We are a driving force of safety, strength and security in America. We are the Generic and Biosimilar Medicines Industry. And we help patients and communities thrive.

Savings from generic and biosimilar medicines bring patients relief from prescription costs, and adds value, state by st...
10/12/2026

Savings from generic and biosimilar medicines bring patients relief from prescription costs, and adds value, state by state! 🇺🇸 On average, the use of generics and biosimilars saved more than $9.3B per state in 2025, with savings ranging from $651M in Alaska to $41.8B in California. Prioritizing the utilization of lower-cost generic and biosimilar medicines is a way for employers and state payers to ensure access and manage spending. Learn more: https://accessiblemeds.org/resources/reports/2026-savings-report/

Acting Commissioner of FDA, Kyle Diamantas, to Keynote 2026. Explore three learning tracks over the three-day event, i...
10/09/2026

Acting Commissioner of FDA, Kyle Diamantas, to Keynote 2026. Explore three learning tracks over the three-day event, including a biosimilars specific path! Register Today: https://grxbiosims.org

While approximately 9 out of every 10 prescriptions filled the U.S. are generics and biosimilars, the volume share of pr...
10/08/2026

While approximately 9 out of every 10 prescriptions filled the U.S. are generics and biosimilars, the volume share of prescriptions dispensed of these lower-cost medicines varies significantly across therapy areas. For instance, generics account for 97% or more of the prescriptions for hypertension and mental health. However, for other therapy areas, it is much lower. Yet even when generic drugs are widely used, brand-name drugs may still account for the majority of spending. Learn more from our recently released U.S. savings report: https:// accessiblemeds.org/resources/reports/2026-savings-report/

In the U.S., what makes generic medicines structurally different from brand drugs is not chemistry. It’s economics!Gener...
10/06/2026

In the U.S., what makes generic medicines structurally different from brand drugs is not chemistry. It’s economics!

Generics and biosimilars operate in distinct markets from their brand counterparts. Here’s an example that shows the uniqueness of the generic medicines market compared to brand drugs: In 2025, for 1,106 molecules, the entire generics market cultivated $57B in sales. At the same time, only two brand drug products – Mounjaro and Ozempic – captured $76.4 billion in sales. That’s nearly 50% more in sales from two brand drug products alone, than all 1,106 generic molecules combined. If not prioritized through policy and regulatory actions, lower-cost generic and biosimilar medicines could be forced out of the U.S. market, entirely. This can yield supply chain disruptions and drug shortages, and increase the potential for economic uncertainties and national security threats.

Learn more in our latest savings report: https://accessiblemeds.org/resources/reports/2026- savings-report/

10/05/2026

Registration is now open for IGBA's Global Biosimilars Week 2026 Webinar Event!

Join our very own Giuseppe Randazzo on October 21, 2026, as he moderates a robust panel around the incredible benefit to patients, communities and health systems that can stem from prioritizing biosimilar medicines across the policy, legal and regulatory landscapes.
Association for Accessible Medicines

NEW THIS MONTH! The 2026 U.S. Generic & Biosimilar Medicines Savings Report shows $3.6 TRILLION of savings in the last d...
10/01/2026

NEW THIS MONTH! The 2026 U.S. Generic & Biosimilar Medicines Savings Report shows $3.6 TRILLION of savings in the last decade, positioning these lower-cost treatment options as a force of strength and security for both the U.S. healthcare ecosystem and the economy. Access the full report to learn how generic & biosimilar medicines are driving America FORWARD! https://accessiblemeds.org/resources/reports/2026- savings-report/

Address

601 New Jersey Avenue NW, Suite 850
Washington D.C., DC
20001

Telephone

+12022497100

Website

Alerts

Be the first to know and let us send you an email when Association for Accessible Medicines posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share

Category